Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Coherus Oncology (CHRS) SEC filings are available on StockTitan?
StockTitan tracks 53 SEC filings for Coherus Oncology (CHRS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Coherus Oncology (CHRS)?
The most recent SEC filing for Coherus Oncology (CHRS) was filed on August 7, 2025.